PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
28117385-7	2017	RESULTS: Of 265 PREVAIL patients with radiographic progression and evaluable PSA levels on the enzalutamide arm, nearly one-quarter had a nonrising PSA.	enzalutamide	95-107	aminopeptidase puromycin sensitive	Homo sapiens	77-80	
28614217-0	2017	PSA declines and survival in patients with metastatic castration-resistant prostate cancer treated with enzalutamide: A retrospective case-report study.	enzalutamide	104-116	aminopeptidase puromycin sensitive	Homo sapiens	0-3	
28614217-1	2017	RATIONALE: PSA responses have been associated with a survival benefit in patients treated with enzalutamide in retrospective analyses.	enzalutamide	95-107	aminopeptidase puromycin sensitive	Homo sapiens	11-14	
28614217-2	2017	PATIENT CONCERNS: However the prognostic value of PSA declines in highly pretreated patients receiving enzalutamide remains to be defined.	enzalutamide	103-115	aminopeptidase puromycin sensitive	Homo sapiens	50-53	
28614217-9	2017	LESSONS: Our study supports the prognostic value of PSA declines in heavily treated patients receiving enzalutamide.	enzalutamide	103-115	aminopeptidase puromycin sensitive	Homo sapiens	52-55	
28117385-10	2017	CONCLUSIONS: Non-rising PSA at radiographic progression is a common phenomenon in mCRPC patients treated with enzalutamide.	enzalutamide	110-122	aminopeptidase puromycin sensitive	Homo sapiens	24-27	
28117385-11	2017	As restaging in advanced prostate cancer patients is often guided by increases in PSA levels, our results demonstrate that disease progression on enzalutamide can occur without rising PSA levels.	enzalutamide	146-158	aminopeptidase puromycin sensitive	Homo sapiens	82-85	
25131864-8	2014	Enzalutamide was associated with significant benefits over the placebo considering time-to-event outcomes(i.e. prolonged overall survival[OS], delayed time to prostatic specific antigen[PSA]progression[TTPP], prolonged radiographic progression free survival[rPFS], time to the first skeletal related event[SRE])as well as objective response outcomes(i.e. PSA, soft tissue, and quality of life[QOL]).	enzalutamide	0-12	aminopeptidase puromycin sensitive	Homo sapiens	186-189	
25131864-8	2014	Enzalutamide was associated with significant benefits over the placebo considering time-to-event outcomes(i.e. prolonged overall survival[OS], delayed time to prostatic specific antigen[PSA]progression[TTPP], prolonged radiographic progression free survival[rPFS], time to the first skeletal related event[SRE])as well as objective response outcomes(i.e. PSA, soft tissue, and quality of life[QOL]).	enzalutamide	0-12	aminopeptidase puromycin sensitive	Homo sapiens	355-358	
34885192-3	2021	PCa cells were individually sorted in self-seeding microwells, cultured for 24 h, and then exposed to several drugs to induce (R1881) or inhibit (Enzalutamide/Abiraterone) the secretion of a protein (PSA).	enzalutamide	146-158	aminopeptidase puromycin sensitive	Homo sapiens	200-203	
34885192-8	2021	PSA production decreased in the majority of cells after exposure to enzalutamide and abiraterone.	enzalutamide	68-80	aminopeptidase puromycin sensitive	Homo sapiens	0-3	
34385241-0	2021	A phase 3 randomised study of enzalutamide plus leuprolide and enzalutamide monotherapy in high-risk non-metastatic hormone-sensitive prostate cancer with rising PSA after local therapy: EMBARK study design.	enzalutamide	30-42	aminopeptidase puromycin sensitive	Homo sapiens	162-165	
34385241-0	2021	A phase 3 randomised study of enzalutamide plus leuprolide and enzalutamide monotherapy in high-risk non-metastatic hormone-sensitive prostate cancer with rising PSA after local therapy: EMBARK study design.	enzalutamide	63-75	aminopeptidase puromycin sensitive	Homo sapiens	162-165	
34385241-5	2021	The main objective of EMBARK is the comparative assessment of enzalutamide plus leuprolide (luteinising hormone-releasing hormone agonist (LHRHa)) or enzalutamide monotherapy versus monotherapy LHRHa to improve metastasis-free survival (MFS) in patients with high-risk nmCSPC PSA recurrence after definitive therapy.	enzalutamide	62-74	aminopeptidase puromycin sensitive	Homo sapiens	276-279	
34385241-5	2021	The main objective of EMBARK is the comparative assessment of enzalutamide plus leuprolide (luteinising hormone-releasing hormone agonist (LHRHa)) or enzalutamide monotherapy versus monotherapy LHRHa to improve metastasis-free survival (MFS) in patients with high-risk nmCSPC PSA recurrence after definitive therapy.	enzalutamide	150-162	aminopeptidase puromycin sensitive	Homo sapiens	276-279